Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy

Area of Science:

• Radiopharmaceutical chemistry
• Bioorthogonal chemistry
• Cancer imaging and therapy

Background:

• Bioorthogonal chemistry reactions are gaining traction in the radiopharmaceutical field due to their speed and selectivity.
• These reactions are valuable for creating novel radiopharmaceuticals and for bioconjugation.
• Emerging applications include in vivo pretargeting strategies for cancer treatment and imaging.

Purpose of the Study:

• To review the potential of various bioorthogonal chemistry reactions for pretargeting in cancer imaging and therapy.
• To highlight how these reactions can improve image quality, therapeutic index, and reduce radiation dose to non-target tissues.

Main Methods:

• Review of current literature on bioorthogonal chemistry applications in radiopharmaceuticals.
• Focus on in vivo pretargeting strategies utilizing bioorthogonal reactions.
• Analysis of the potential benefits for cancer diagnostics and therapeutics.

Main Results:

• Bioorthogonal reactions demonstrate significant utility in radiopharmaceutical construction and bioconjugation.
• In vivo pretargeting strategies using these reactions are emerging for cancer applications.
• Successful implementation could enhance image quality and therapeutic efficacy while minimizing off-target radiation.

Conclusions:

• Bioorthogonal chemistry holds substantial promise for advancing cancer pretargeting strategies.
• This approach offers a pathway to improved cancer imaging and therapy with enhanced safety profiles.
• Further research into various bioorthogonal reactions is warranted for successful clinical translation.